| Product Code: ETC12626317 | Publication Date: Apr 2025 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 New Zealand Oncology Anti-Cancer Drugs Market Overview |
3.1 New Zealand Country Macro Economic Indicators |
3.2 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 New Zealand Oncology Anti-Cancer Drugs Market - Industry Life Cycle |
3.4 New Zealand Oncology Anti-Cancer Drugs Market - Porter's Five Forces |
3.5 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume Share, By Cancer Type, 2021 & 2031F |
3.7 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume Share, By Therapy Type, 2021 & 2031F |
3.9 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 New Zealand Oncology Anti-Cancer Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in New Zealand |
4.2.2 Technological advancements in oncology drugs |
4.2.3 Growing investment in research and development for anti-cancer drugs |
4.3 Market Restraints |
4.3.1 Stringent regulatory approval processes for new drugs |
4.3.2 High cost associated with oncology drugs |
4.3.3 Limited access to specialized healthcare facilities in certain regions of New Zealand |
5 New Zealand Oncology Anti-Cancer Drugs Market Trends |
6 New Zealand Oncology Anti-Cancer Drugs Market, By Types |
6.1 New Zealand Oncology Anti-Cancer Drugs Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Drug Class, 2021 - 2031F |
6.1.3 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Chemotherapy, 2021 - 2031F |
6.1.4 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Immunotherapy, 2021 - 2031F |
6.1.5 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Hormone Therapy, 2021 - 2031F |
6.1.6 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Targeted Therapy, 2021 - 2031F |
6.1.7 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Precision Medicine, 2021 - 2031F |
6.2 New Zealand Oncology Anti-Cancer Drugs Market, By Cancer Type |
6.2.1 Overview and Analysis |
6.2.2 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Lung Cancer, 2021 - 2031F |
6.2.3 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Breast Cancer, 2021 - 2031F |
6.2.4 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Prostate Cancer, 2021 - 2031F |
6.2.5 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Colorectal Cancer, 2021 - 2031F |
6.2.6 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Leukemia, 2021 - 2031F |
6.3 New Zealand Oncology Anti-Cancer Drugs Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Oral, 2021 - 2031F |
6.3.3 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Intravenous, 2021 - 2031F |
6.3.4 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Subcutaneous, 2021 - 2031F |
6.3.5 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Topical, 2021 - 2031F |
6.3.6 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Intramuscular, 2021 - 2031F |
6.4 New Zealand Oncology Anti-Cancer Drugs Market, By Therapy Type |
6.4.1 Overview and Analysis |
6.4.2 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Targeted Therapy, 2021 - 2031F |
6.4.3 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Immunotherapy, 2021 - 2031F |
6.4.4 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Hormone Therapy, 2021 - 2031F |
6.4.5 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Chemotherapy, 2021 - 2031F |
6.4.6 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Combination Therapy, 2021 - 2031F |
6.5 New Zealand Oncology Anti-Cancer Drugs Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Hospital Pharmacies, 2021 - 2031F |
6.5.3 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Retail Pharmacies, 2021 - 2031F |
6.5.4 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Online Pharmacies, 2021 - 2031F |
6.5.5 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Specialty Pharmacies, 2021 - 2031F |
6.5.6 New Zealand Oncology Anti-Cancer Drugs Market Revenues & Volume, By Mail Order Pharmacies, 2021 - 2031F |
7 New Zealand Oncology Anti-Cancer Drugs Market Import-Export Trade Statistics |
7.1 New Zealand Oncology Anti-Cancer Drugs Market Export to Major Countries |
7.2 New Zealand Oncology Anti-Cancer Drugs Market Imports from Major Countries |
8 New Zealand Oncology Anti-Cancer Drugs Market Key Performance Indicators |
8.1 Average time to market for new anti-cancer drugs |
8.2 Number of clinical trials conducted for oncology drugs in New Zealand |
8.3 Percentage of oncologists adopting new treatment protocols |
8.4 Patient survival rates post-treatment |
8.5 Adoption rate of personalized medicine approaches in cancer treatment |
9 New Zealand Oncology Anti-Cancer Drugs Market - Opportunity Assessment |
9.1 New Zealand Oncology Anti-Cancer Drugs Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 New Zealand Oncology Anti-Cancer Drugs Market Opportunity Assessment, By Cancer Type, 2021 & 2031F |
9.3 New Zealand Oncology Anti-Cancer Drugs Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 New Zealand Oncology Anti-Cancer Drugs Market Opportunity Assessment, By Therapy Type, 2021 & 2031F |
9.5 New Zealand Oncology Anti-Cancer Drugs Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 New Zealand Oncology Anti-Cancer Drugs Market - Competitive Landscape |
10.1 New Zealand Oncology Anti-Cancer Drugs Market Revenue Share, By Companies, 2024 |
10.2 New Zealand Oncology Anti-Cancer Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here